BCAB
BioAtla, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.74
+31.44%Year over year
Reported trailing growth
- Revenue
- -22.7%
- EBITDA
- +52.0%
- EBIT
- +50.4%
- EPS
- +42.4%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -81.8%
- EBITDA
- +14.0%
- EBIT
- +19.8%
- Net income
- +14.6%
- EPS
- +29.9%
- Free cash flow
- +33.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026